Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Inno

Showing results (81-90 of 101) with videos related to

Pageof 11
Sort By:
Cancer Immunology, Immunotherapy : CII|July 12, 2025
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational studyAlessandro Inno, Antonello Veccia, Ettore D'Argento, et al.
Journal of Clinical Medicine|February 13, 2026
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World StudyAntonello Veccia, Ettore D'Argento, Floriana Morgillo, et al.
Plos One|September 5, 2015
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Alessandro Inno, Elena Fiorio, et al.
Frontiers in Cardiovascular Medicine|October 3, 2023
Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionalsIrma Bisceglia, Maria Laura Canale, Nicola Silvestris, et al.
Frontiers in Cardiovascular Medicine|November 13, 2023
Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionalsIrma Bisceglia, Maria Laura Canale, Nicola Silvestris, et al.
Therapeutic Advances in Medical Oncology|October 22, 2019
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian studyRossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular CarcinomaMarkus W Löffler, Stefania Gori, Francesco Izzo, et al.
Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.
Cancer Treatment and Research Communications|February 18, 2026
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trialChiara Mattioli, Emanuela Olmetto, Marco Banini, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Pageof 11

Showing results (81-90 of 101) with videos related to

Sort By:
Pageof 11
Cancer Immunology, Immunotherapy : CII|July 12, 2025
Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational studyAlessandro Inno, Antonello Veccia, Ettore D'Argento, et al.
Journal of Clinical Medicine|February 13, 2026
Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World StudyAntonello Veccia, Ettore D'Argento, Floriana Morgillo, et al.
Plos One|September 5, 2015
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Alessandro Inno, Elena Fiorio, et al.
Frontiers in Cardiovascular Medicine|October 3, 2023
Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionalsIrma Bisceglia, Maria Laura Canale, Nicola Silvestris, et al.
Frontiers in Cardiovascular Medicine|November 13, 2023
Corrigendum: Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionalsIrma Bisceglia, Maria Laura Canale, Nicola Silvestris, et al.
Therapeutic Advances in Medical Oncology|October 22, 2019
Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian studyRossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2022
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular CarcinomaMarkus W Löffler, Stefania Gori, Francesco Izzo, et al.
Journal for Immunotherapy of Cancer|November 6, 2020
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practiceAlessio Cortellini, Marco Tucci, Vincenzo Adamo, et al.
Cancer Treatment and Research Communications|February 18, 2026
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trialChiara Mattioli, Emanuela Olmetto, Marco Banini, et al.
Oncoimmunology|February 1, 2020
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 studyAlessio Cortellini, Sebastiano Buti, Melissa Bersanelli, et al.
Pageof 11